Primo Lara and Monty Pal discuss this exciting time in the evolving paradigm for the treatment of kidney cancer. They focus their discussion on the groundbreaking data presented at ASCO GU on the KEYNOTE 426 trial which demonstrated that the combination of pembrolizumab plus axitinib was superior to the VEGF RTKI, sunitinib. Overall survival with the combination demonstrated a 46% reduction in…
erectile dysfunction, inflatable penile prosthesis (IPP), Satisfaction Survey for Inflatable Penile Implant (SSIPI), better patient care for Spanish speaking individuals undergoing inflatable penile prosthesis surgery.
At the 2025 UCSF-UCLA PSMA Conference, Amir Iravani compares FDA-approved PSMA PET agents (gallium-68 PSMA-11, DCFPyL, rhPSMA-7.3) for prostate cancer imaging. Dr. Iravani notes similar…
Peyronie’s Disease, Molecular Hallmarks of Peyronie’s Disease, tyrosine kinase inhibitor, transforming growth factor-beta (TGF-β), Matrix metalloproteinases (MMP) enzymes, Tissue inhibitors of metalloproteinases proteins (TIMP), pirfenidone,…
Testicular cancer, Testicular germ cell tumor (TGCT), Retroperitoneal Lymph Node Dissection (RPLND), pathological lymph node staging, clinical stage (CS) II seminomatous TGCT.
Benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), Holmium Laser Enucleation of the prostate cancer (HoLEP), Advancing Holmium Laser Enucleation, American Urological Association Symptom…
Oliver Sartor host Ken Herrmann to discuss tumor dosimetry findings from a VISION trial substudy examining lutetium PSMA therapy in prostate cancer patients. Dr. Herrmann…
Fecal Incontinence, Sacral neuromodulation, sacral nerve stimulation (SNS), Sacral Nerve Stimulator for Management of Fecal Incontinence, overactive bladder, InterStim™ device.
UroToday – GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and…
Ashish Kamat speaks with Nimira Alimohamed about the evolution of circulating tumor DNA (ctDNA) in muscle invasive bladder cancer management. Dr. Alimohamed explains that current…
Treatment options for metastatic urothelial carcinoma, cisplatin-based chemotherapy, combination enfortumab vedotin–pembrolizumab, Nivolumab as adjuvant treatment in high-risk muscle-invasive UC.
